Tango Therapeutics (TNGX) Price & Analysis

Compare

443 Followers

TNGX Stock Chart & Stats

$17.30

-$0.22(-6.34%)

At close: Jan 08 4:00 PM EST

$17.30

-$0.22(-6.34%)

Day’s Range― - ―

52-Week Range$1.03 - $17.63

Previous CloseN/A

Volume187.94K

Average Volume (3M)3.04M

Market Cap

$2.47B

Enterprise Value$1.93B

Total Cash (Recent Filing)$343.14M

Total Debt (Recent Filing)$33.57M

Price to Earnings (P/E)―

Beta1.08

Next Earnings

May 13, 2026

EPS Estimate

-0.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding142,688,860

10 Day Avg. Volume3,795,201

30 Day Avg. Volume3,037,748

Financial Highlights & Ratios

PEG Ratio0.38

Price to Book (P/B)2.97

Price to Sales (P/S)16.50

P/FCF Ratio-7.36

Enterprise Value/Market Cap0.78

Enterprise Value/Revenue30.95

Enterprise Value/Gross Profit31.80

Enterprise Value/Ebitda-18.38

Forecast

1Y Price Target

$20.67

Price Target Upside19.48% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-1.28

Revenue Forecast (FY)$7.49M

Bulls Say, Bears Say

Bulls Say

Clinical Development MomentumRobust enrollment and favorable safety observations in the combination study, together with leading monotherapy clinical data for the PRMT5 inhibitor and multiple collaboration interests, increase the likelihood of an early proof‑of‑concept clinical success and potential pivotal study planning.

Preclinical Efficacy Of Partner AssetPreclinical results show the partner's pan‑RAS therapy delivers substantially stronger target binding and more potent inhibition of cancer cell growth than a leading comparator, supporting a compelling rationale for the combination approach.

Strategic CollaborationAnalyst notes a clinical collaboration and supply agreement to test a partner's pan‑RAS molecular glue with vopimetostat, creating a clear pathway to evaluate complementary mechanisms that could enhance treatment potency.

Bears Say

Regulatory RiskAnalyst notes meaningful regulatory uncertainty for vopimetostat, indicating approval risk that could weigh on investor expectations and the stock's performance.

Tango Therapeutics News

Tango Therapeutics price target raised to $20 from $19 at Mizuho

Mizuho raised the firm’s price target on Tango Therapeutics (TNGX) to $20 from $19 and keeps an Outperform...

4d ago

TNGX

Tango Therapeutics price target raised to $24 from $15 at Stifel

Stifel analyst Laura Prendergast raised the firm’s price target on Tango Therapeutics (TNGX) to $24 from $15 and...

6d ago

TNGX

Tango Therapeutics price target raised to $19 from $15 at Wedbush

Wedbush raised the firm’s price target on Tango Therapeutics (TNGX) to $19 from $15 and keeps an Outperform...

9d ago

TNGX

Tango Therapeutics price target raised to $20 from $18 at Guggenheim

Guggenheim analyst Michael Schmidt raised the firm’s price target on Tango Therapeutics (TNGX) to $20 from $18 and...

9d ago

ERAS

TNGX

Tango Therapeutics price target raised to $27 from $13 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Tango Therapeutics (TNGX) to $27 from $13 and keeps a...

9d ago

TNGX

Midday Fly By: Stocks tumble as oil prices climb again

Stocks are lower at midday as traders keep an eye on rising oil prices. U.S. crude oil prices...

10d ago

Erasca, Tango Therapeutics enter clinical collaboration, supply agreement

Erasca (ERAS) announced a clinical trial collaboration and supply agreement, CTCSA, with Tango Therapeutics (TNGX) to evaluate Erasca’s...

10d ago

ERAS

TNGX

Tango Therapeutics reports Q4 EPS (29c), consensus (33c)

“We enter 2026 with a clear focus on execution, building on the significant progress achieved across our development...

10d ago

TNGX

Tango Therapeutics weakness an ‘over reaction,’ says Stifel

Stifel believes Tango Therapeutics (TNGX) shares are reacting in large part due to Revolution Medicines’ (RVMD) announcement of...

17d ago

BMY

RVMD

Tango Therapeutics initiated with an Outperform at Mizuho

Mizuho initiated coverage of Tango Therapeutics (TNGX) with an Outperform rating and $19 price target The firm says...

20d ago

TNGX

Tango Therapeutics appoints new CEO amid leadership transition

An update from Tango Therapeutics ( ($TNGX) ) is now available. On January 8, 2026, Tango Therapeutics announced...

2M ago

TNGX

Tango Therapeutics Adds Independent Director to Strengthen Governance

Tango Therapeutics ( ($TNGX) ) has shared an announcement. On January 2, 2026, Tango Therapeutics, Inc. expanded its...

2M ago

TNGX

Strategic Positioning and Synergy Potential Drive Buy Rating for Tango Therapeutics’ Vopimetostat

Tango Therapeutics (TNGX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Laura Prendergast. Laura Prendergast’s...

3M ago

TNGX

Tango Therapeutics Enters New Sales Agreement with Leerink

Tango Therapeutics ( ($TNGX) ) has provided an update. On November 21, 2025, Tango Therapeutics entered into a...

4M ago

TNGX

TNGX FAQ

What was Tango Therapeutics’s price range in the past 12 months?

Tango Therapeutics lowest stock price was $1.03 and its highest was $17.63 in the past 12 months.

What is Tango Therapeutics’s market cap?

Tango Therapeutics’s market cap is $2.47B.

When is Tango Therapeutics’s upcoming earnings report date?

Tango Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 59 days.

How were Tango Therapeutics’s earnings last quarter?

Tango Therapeutics released its earnings results on Mar 05, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.318 by $0.028.

Is Tango Therapeutics overvalued?

According to Wall Street analysts Tango Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tango Therapeutics pay dividends?

Tango Therapeutics does not currently pay dividends.

What is Tango Therapeutics’s EPS estimate?

Tango Therapeutics’s EPS estimate is -0.31.

How many shares outstanding does Tango Therapeutics have?

Tango Therapeutics has 142,688,860 shares outstanding.

What happened to Tango Therapeutics’s price movement after its last earnings report?

Tango Therapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.318. Following the earnings report the stock price went up 36.275%.

Which hedge fund is a major shareholder of Tango Therapeutics?

Currently, no hedge funds are holding shares in TNGX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Tango Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-50.30%

Trailing 12-Months

Asset Growth

24.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Tango Therapeutics (TNGX) Earnings & Revenues

Historic Earnings Reports

TNGX Stock 12 Month Forecast

Average Price Target

$20.67

▲(19.48% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","14":"$14","21":"$21","28":"$28"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,7,14,21,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.53,12.719999999999999,13.91,15.1,16.29,17.479999999999997,18.669999999999998,19.86,21.049999999999997,22.24,23.43,24.619999999999997,25.81,{"y":27,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.53,12.233076923076922,12.936153846153847,13.63923076923077,14.342307692307692,15.045384615384616,15.74846153846154,16.451538461538462,17.154615384615386,17.85769230769231,18.560769230769232,19.263846153846156,19.96692307692308,{"y":20.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.53,11.719999999999999,11.91,12.1,12.29,12.48,12.67,12.86,13.05,13.24,13.43,13.620000000000001,13.81,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.11,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.86,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.94,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.53,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >